Related Experiment Videos
Hypertension and the heart
1Department of Medicine IV, University of Erlangen-Nürnberg, Germany. roland.schmieder@rzmail.uni-erlangen.de
Insights
Left ventricular hypertrophy is a significant risk factor for heart disease. Certain blood pressure medications, like ACE inhibitors, effectively reduce left ventricular mass, improving cardiovascular outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular (LV) hypertrophy is a key independent risk factor for cardiovascular morbidity and mortality.
- LV hypertrophy in hypertension involves both hemodynamic and non-hemodynamic factors.
- Regression of LV hypertrophy is a therapeutic goal, linked to reduced cardiovascular complications.
Purpose of the Study:
- To investigate if different antihypertensive drugs vary in their efficacy for reducing LV mass.
- To compare the effects of various drug classes on LV hypertrophy regression.
Main Methods:
- Review of comparative studies and meta-analyses on antihypertensive drug effects on LV mass.
- Analysis of data comparing ACE inhibitors, calcium channel blockers, beta-blockers, diuretics, and ARBs.
Main Results:
- Angiotensin-converting enzyme (ACE)-inhibitors and calcium channel blockers show greater potency in reducing LV hypertrophy compared to beta-blockers.
- Diuretics exhibit intermediate efficacy in LV mass reduction.
- Angiotensin II AT1-receptor blockers demonstrate efficacy comparable to ACE-inhibitors, sometimes superior to beta-blockers and diuretics.
Conclusions:
- Antihypertensive drug choice can significantly impact LV mass regression.
- ACE inhibitors, CCBs, and ARBs are highlighted for their effectiveness in reducing LV hypertrophy.
- Further research into drug-specific effects on LV remodeling is warranted.
Abstract:
It has been clearly demonstrated that left ventricular (LV) hypertrophy is a strong blood pressure independent risk factor for cardiovascular morbidity and mortality in the general population, in primary and secondary hypertension and in cardiac patients. LV hypertrophy in arterial hypertension develops in response to an increased afterload, but underlying pathophysiological mechanisms include a variety of non-haemodynamic factors. Due to the prognostic importance of LV hypertrophy, normalisation of LV mass emerged as a desirable goal of antihypertensive treatment. Indeed, several prospective studies now indicate that regression of LV hypertrophy reduced cardiovascular complications. As a consequence, the question was raised whether certain antihypertensive drugs differ in their ability to reduce LV mass. Several comparative studies and meta-analyses have been carried out to resolve this issue. The available data seem to indicate that angiotensin-converting enzyme (ACE)-inhibitors and calcium channel blockers were more potent than beta-blockers in their ability to reduce LV hypertrophy, with diuretics in the intermediate range. The role of new antihypertensive agents such as angiotensin II AT1-receptor blockers appears similar to the one of ACE-inhibitors, since in some studies angiotensin II AT1-receptor blockers were superior to beta-blockers and diuretics. Various aspects of LV hypertrophy including its prevalence, determinants, prognosis and regression are discussed in this article.